Payment overview · 2025
General Payments
$200.08
10 reported records · 8 companies
Healthcare provider profile · identity verified
Madiha Farhat, MD
Allopathic & Osteopathic Physicians|Family Medicine · PLAINWELL, MI · NPI 1427251701
Verified facts
What the public records show
CMS Open Payments records show Madiha Farhat, MD received $200.08 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.64 | 26.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.86 | 13.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.70 | 11.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.16 | 11.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.12 | 10.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.56 | 9.8% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.42 | 9.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.62 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.08 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.64 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 79 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 436 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 109 |
| Lisinopril | Lisinopril | 318 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 103 |
| Losartan Potassium | Losartan Potassium | 272 | 80 |
| Metformin Hcl | Metformin Hcl | 253 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 230 | 49 |
| Omeprazole | Omeprazole | 204 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 58 |
| Simvastatin | Simvastatin | 152 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 136 | 30 |
| Gabapentin | Gabapentin | 126 | 34 |
| Alendronate Sodium | Alendronate Sodium | 125 | 38 |
| Sertraline Hcl | Sertraline Hcl | 120 | 41 |
| Meloxicam | Meloxicam | 111 | 33 |
| Furosemide | Furosemide | 108 | 38 |
| Trazodone Hcl | Trazodone Hcl | 105 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 20 |
| Potassium Chloride | Potassium Chloride | 92 | 26 |
| Alprazolam | Alprazolam | 90 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 28 |
| Montelukast Sodium | Montelukast Sodium | 84 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 25 |
| Eliquis | Apixaban | 79 | 25 |
| Tramadol Hcl | Tramadol Hcl | 78 | 22 |
| Lovastatin | Lovastatin | 77 | 20 |
| Jardiance | Empagliflozin | 73 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 23 |
| Allopurinol | Allopurinol | 67 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 20 |
| Metformin Hcl Er | Metformin Hcl | 61 | 22 |
| Prednisone | Prednisone | 59 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Januvia | Sitagliptin Phosphate | 57 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 18 |
| Ezetimibe | Ezetimibe | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Donepezil Hcl | Donepezil Hcl | 53 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 20 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Glipizide | Glipizide | 49 | 15 |
| Trulicity | Dulaglutide | 48 | 12 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Cephalexin | Cephalexin | 40 | 26 |
| Carvedilol | Carvedilol | 39 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 12 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Ozempic | Semaglutide | 32 | 12 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Famotidine | Famotidine | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 15 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tri-Lo-Mili | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.08 · 10 records | Novo Nordisk Inc | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FANAPT, GARDASIL 9, MOUNJARO, NURTEC ODT, Ozempic, Qelbree, Rybelsus, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error